Targeted therapy for cancers with a specific gene change
Part of Cancer clinical trials.
This trial tests an experimental drug called GenSci145, which may target cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments. The goal is to see if it can shrink tumors or slow cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- Your tumor has a specific change called a PIK3CA mutation.
- Your cancer has not responded to standard treatments or no standard treatment is available.
- You have at least one tumor that can be measured on scans.
- You are generally healthy enough to carry out everyday activities (ECOG score 0 or 1).
- Your blood counts, liver, kidney, and blood sugar levels are within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
This trial tests an experimental pill called GenSci122 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This trial tests a new pill (CGT6297) that targets cancer cells with a specific PIK3CA gene change. It may be an option for people with certain advanced solid tumors, including endometrial or breast cancer, after standard treatments have stopped working.
This study tests a new drug called REC-7735 for people with solid tumors that have a specific genetic change (PIK3CA H1047R). The drug targets this change to try to stop the cancer from growing.
This study tests a new drug called LAE118, which targets cancers with a specific gene change called PIK3CA. The drug is given alone or with other treatments for advanced solid tumors, and the goal is to see if it is safe and can help shrink tumors.
This trial tests for a specific gene change (PIK3CA mutation) in your breast cancer cells. The results will help doctors decide if a targeted treatment is right for you. It's for people with hormone-receptor-positive, HER2-negative breast cancer that has spread and not yet been treated in that setting.
Hear when a new Locally Advanced or Metastatic Solid Tumors With PIK3CA-mutated trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.